AKR1C14 Inhibitors
AKR1C14 inhibitors belong to a specialized class of chemical compounds that are designed to selectively target and inhibit the enzyme AKR1C14, also known as Aldo-Keto Reductase Family 1 Member C14. AKR1C14 is a member of the aldo-keto reductase superfamily of enzymes, which are involved in the metabolism of various endogenous and exogenous compounds in the human body. This particular enzyme, AKR1C14, plays a crucial role in the conversion of certain ketones and aldehydes into their corresponding alcohols, primarily within the context of steroid metabolism.
The development of AKR1C14 inhibitors is of significant interest in the field of chemical biology and drug discovery. These inhibitors are designed with the aim of modulating the activity of AKR1C14, potentially impacting steroid metabolism and related physiological processes. By selectively inhibiting AKR1C14, these compounds may have the capacity to regulate the production of specific steroid metabolites, which could have downstream effects on various biological pathways. The design and optimization of AKR1C14 inhibitors involve a thorough understanding of the enzyme's structure and function, enabling researchers to create compounds that can effectively bind to and inhibit its activity. This class of inhibitors has the potential to serve as valuable tools for studying steroid metabolism and may have implications in various research areas, though their specific applications would depend on the context of the research and their effectiveness in modulating AKR1C14 activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Flufenamic acid | 530-78-9 | sc-205699 sc-205699A sc-205699B sc-205699C | 10 g 50 g 100 g 250 g | $27.00 $79.00 $154.00 $309.00 | 1 | |
NSAID that can inhibit AKRs by interacting with the enzyme's substrate-binding site. | ||||||
Naproxen | 22204-53-1 | sc-200506 sc-200506A | 1 g 5 g | $24.00 $41.00 | ||
Possesses the ability to bind to the AKR active site, potentially reducing enzyme activity. | ||||||
Ibuprofen | 15687-27-1 | sc-200534 sc-200534A | 1 g 5 g | $53.00 $88.00 | 6 | |
Can bind to the AKR active site, thereby obstructing access to the enzyme's substrates. | ||||||
Medroxyprogesterone | 520-85-4 | sc-250297 | 100 mg | $103.00 | ||
Progestin that can modulate AKR activity by competing with natural steroid substrates. | ||||||
18 β-Glycyrrhetinic Acid | 471-53-4 | sc-205573B sc-205573 sc-205573A sc-205573C sc-205573D | 1 g 5 g 10 g 25 g 100 g | $29.00 $55.00 $87.00 $132.00 $319.00 | 3 | |
Inhibits AKRs by binding to the enzyme's active site, preventing substrate access. | ||||||
Vitamin K3 | 58-27-5 | sc-205990B sc-205990 sc-205990A sc-205990C sc-205990D | 5 g 10 g 25 g 100 g 500 g | $26.00 $36.00 $47.00 $136.00 $455.00 | 3 | |
Interacts with AKRs and potentially other related reductases, affecting enzyme function. | ||||||
Phenylbutazone | 50-33-9 | sc-204843 | 5 g | $32.00 | 1 | |
Has the potential to inhibit AKR1C14 by binding to its active site due to its structure similarity to NSAIDs. | ||||||
Diclofenac acid | 15307-86-5 | sc-357332 sc-357332A | 5 g 25 g | $109.00 $298.00 | 5 | |
May inhibit AKRs including AKR1C14 by binding to the active site, thereby competing with endogenous substrates. | ||||||
Sulindac | 38194-50-2 | sc-202823 sc-202823A sc-202823B | 1 g 5 g 10 g | $32.00 $86.00 $150.00 | 3 | |
Can bind to and inhibit AKR enzymes, altering their reduction of substrates. | ||||||